

## AXIRON NET SALES, QUARTER TO 30 JUNE 2013

Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of US\$47 million in its financial results for the quarter ended 30 June 2013, up from US\$37 million for the previous quarter to 31 March 2013.

Axiron net sales for Acrux's financial year ended 30 June 2013 are shown in the following table:

Q3 2012	Q4 2012	Q1 2013	Q2 2013	<b>Total FY 2013</b>
US\$16m	US\$24m	US\$37m	US\$47m	<b>US\$124m</b>

For the year ended 30 June 2013, Acrux earned royalties from Axiron of \$14 million, up from \$6 million in the previous year.

Acrux expects the average royalty percentage of net sales to increase in the year ending 30 June 2014. In addition to royalties, Acrux will receive a milestone payment of US\$25 million in March 2014 if the worldwide net sales of Axiron in the 2013 calendar year exceed US\$100 million. Net sales in the first half of the calendar year were US\$84 million.

### Contact

Jon Pilcher, CFO: 0438 422 271

### About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative liquid technology to administer drugs through the skin.
- Acrux has products marketed by licensees in the United States, Europe, Canada and Australia and in registration or development.